SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

TG Therapeutics Raises 2026 Revenue Forecast Above $1B After Q3 Topline Beat

TG Therapeutics reported a better-than-expected third-quarter topline and raised its full-year 2026 global revenue forecast, citing growth in Briumvi. Shares were up around 2%.

TGTX
SquawkNews Desk

TG Therapeutics (TGTX) was in the spotlight on Monday after the biotech firm reported a better-than-expected third-quarter topline and raised its full-year 2026 global revenue forecast, driven by strong growth in its multiple sclerosis (MS) treatment, Briumvi.TGTX shares were up around 2% at the ti…

Related stories

Lilly’s Foundayo Meets Main Goal in Late-Stage Sleep Apnea Study Eli Lilly said its oral weight-loss drug Foundayo met the main goal in a late-stage study of adults with moderate-to-severe obstructive sleep apnea and obesity. M impact | EQUITY | Nov 09, 2026, 02:39 PM UTC Canaccord Genuity Reschedules Fiscal Q2 2027 Results Release Canaccord Genuity moved the release of its second-quarter fiscal 2027 results and supplementary information from Nov. 10 to after the Canadian market close on Nov. 16, 2026. M impact | EQUITY | Nov 09, 2026, 02:34 PM UTC Remitly Reports Q3 Revenue Growth, Raises 2026 Guidance and Launches Brazil Service Remitly reported third-quarter revenue of $509.8 million, up 22%, and net income of $67.6 million. It raised full-year 2026 revenue and EBITDA guidance, expanded its share buyback M impact | EQUITY | Nov 09, 2026, 02:34 PM UTC Exascale Labs Orders $9.04 Million of NVIDIA B300 GPU Servers From Compal Exascale Labs placed a firm $9.04 million order with Compal for 16 servers equipped with NVIDIA HGX B300 GPUs. Framework arrangements allow orders for up to 128 servers at fixed pr M impact | EQUITY | Nov 09, 2026, 02:33 PM UTC Nasdaq Composite Rises 276.56 Points (1.13%) M impact | EQUITY | Nov 09, 2026, 02:33 PM UTC S&P 500 rises 71.51 points, or 0.97% M impact | EQUITY | Nov 09, 2026, 02:33 PM UTC